Biotechnology Reports

Anyone hoping to see a strong year for biotech IPOs last year was sorely disappointed. A paltry 10 U.S. companies went public last year, down from 13 in 2010. The biggest IPO of 2011 was Clovis

There was a frenzy of medical device deals in 2011, with some big names entering the fray, including pharmaceutical and device titan Johnson & Johnson. In fact, J&J took the top spot on the

by Ryan McBride and Mark Hollmer The general upheaval in the pharma business kept employees on edge and HR departments busy drafting layoff notices last year. Drugmakers slashed thousands of jobs in

In biotech, the right partnering deal can make a company, bringing in cash, expert help and a major league endorsement for the science involved. If deals go bad, as they often do, the subsequent

Michigan is traditionally known for its preeminence in the auto industry and beautiful scenery. It's also gaining recognition for its booming life sciences industry--particularly medical devices.

by Ryan McBride and John Carroll Female biotech executives have been key players in many of the biggest events in the industry this year--Takeda Pharmaceutical's buyout of Nycomed, the merger of

By John Carroll and Ryan McBride If you add up the R&D budgets for the top 15 public biotechs in the world, you'll find a tab that runs right about $10 billion. That's not small change, by any

The trend in pharma GMP warning letters for 2011 is that there are more of them, with a higher proportion of warnings to foreign plants, as the letters in this report illustrate. "The FDA has more

It's that time of year again; time to visit the biotech graveyard to reflect on the developers whose businesses have in one way or another failed. There's a common theme among many of this year's

by Deborah Erickson Scientists have long figured it should be possible to rev up the immune system on command, to give the body's own natural defenses an extra surge of power to attack tumors and